SAN DIEGO, April 23, 2018 (GLOBE NEWSWIRE) — Samumed, LLC, a leader in Wnt research and development, today announced it will present its most recent clinical and preclinical data on the company’s investigational Wnt pathway inhibitors for the treatment of osteoarthritis (SM04690) and tendinopathy (SM04755) at the 2018 Osteoarthritis Research Society International World Congress, to […]

Share on LinkedInShare on FacebookShare on Google+Pin on PinterestEmail this to someone